Subcutaneous ICD in Patients with Hypertrophic Cardiomyopathy: Comparative Outcomes
Hypertrophic cardiomyopathy (HCM) is a genetically diverse myocardial disease associated with ventricular arrhythmias, heart failure, atrial fibrillation, and sudden cardiac death. An implantable cardioverter-defibrillator (ICD) can reduce the risk of fatal ventricular tachycardia or fibrillation in appropriately selected patients, but the choice of system is clinically important, particularly in younger people who may live with their device for decades.
A subcutaneous ICD (S-ICD) places the pulse generator beneath the skin and the electrode alongside the sternum, avoiding transvenous access. This design is attractive for patients with difficult venous anatomy, prior infection, intracardiac shunts, or a high anticipated risk of lead-related complications. Transvenous ICDs (TV-ICDs), however, provide bradycardia pacing, antitachycardia pacing, and in some cases cardiac resynchronization therapy.
Comparative evidence in HCM is growing but remains largely observational. Registries and multicenter cohorts help define real-world outcomes, although treatment selection, age, disease severity, and programming practices can influence the results. A careful assessment therefore requires more than comparing the number of shocks.
Why Device Selection Matters In HCM
Patients with HCM who receive an ICD are often younger than the broader ICD population. They may have a long exposure period during which venous obstruction, lead fracture, inappropriate therapy, infection, and generator replacement become relevant. Avoiding an intravascular lead can be a meaningful advantage, especially when lifelong pacing is not expected.
The S-ICD is designed to detect and terminate ventricular tachyarrhythmias without entering the heart or bloodstream. This may reduce lead extraction complexity and the consequences of systemic infection. The trade-off is functional: the system cannot deliver antitachycardia pacing, chronic bradycardia support, or resynchronization. Those limitations should be considered before implantation rather than after a pacing indication develops.
HCM also creates distinctive sensing challenges. Large QRS complexes, repolarization abnormalities, bundle branch block, and dynamic changes during exercise can increase the risk of double counting or inappropriate detection. Preimplantation screening in multiple postures and, when appropriate, during exertion is central to reducing this risk.
Comparative Clinical Outcomes
Available studies generally show that S-ICD and TV-ICD recipients with HCM have similar rates of appropriate defibrillator therapy over follow-up, although reported estimates vary according to follow-up duration and patient selection. Appropriate shocks reflect treatment of sustained ventricular tachycardia or fibrillation and indicate that both systems can provide effective protection when programmed and implanted correctly.
The most consistent difference concerns antitachycardia pacing. A TV-ICD may terminate selected monomorphic ventricular tachycardias painlessly, whereas an S-ICD usually treats such episodes with a shock. This distinction may be less important in patients whose dominant risk is rapid ventricular fibrillation, but it becomes clinically relevant when recurrent monomorphic ventricular tachycardia or scar-related arrhythmia is present.
Inappropriate shocks can occur with either platform. S-ICD improvements, including dual-zone programming, updated sensing algorithms, and better screening, have reduced earlier concerns, but oversensing remains an important mechanism. TV-ICDs may experience inappropriate therapy from atrial fibrillation, lead noise, or T-wave oversensing. The relative difference between platforms is not uniform across cohorts and is strongly affected by programming and follow-up.
| Outcome or feature | Subcutaneous ICD | Transvenous ICD |
|---|---|---|
| Protection from ventricular fibrillation | Effective when sensing and defibrillation testing are satisfactory | Effective, with an intracardiac lead |
| Antitachycardia pacing | Not available | Available |
| Chronic bradycardia pacing | Not available, except limited post-shock pacing | Available |
| Cardiac resynchronization | Not available | Available with a suitable system |
| Intravascular lead complications | Avoided | Lead fracture, dislodgement, venous obstruction, and infection are possible |
| Systemic infection risk | Generally lower because there is no endovascular lead | Higher when infection involves the bloodstream or intracardiac lead |
| Inappropriate therapy mechanisms | T-wave oversensing, cardiac signal changes, noise | Atrial arrhythmia, lead noise, T-wave oversensing |
| Long-term procedural flexibility | Lead extraction is avoided, but later pacing may require another system | Pacing functions are integrated, but lead management becomes more complex |
Evidence From HCM Cohorts
Published HCM cohorts indicate that S-ICD implantation is feasible, with acceptable procedural success and defibrillation performance in carefully screened patients. Appropriate shocks occur during follow-up, particularly among individuals with prior ventricular arrhythmia or substantial risk markers. These observations support S-ICD use for primary and secondary prevention when pacing is not clinically required.
The comparison is complicated by channeling bias. Patients selected for an S-ICD are often younger, have fewer comorbidities, and lack a pacing indication, while TV-ICD recipients may have more advanced conduction disease or documented ventricular tachycardia. Consequently, a lower complication rate in an S-ICD cohort cannot automatically be attributed to the device alone.
Follow-up duration also matters. Lead-related complications may accumulate gradually, whereas perioperative complications and inappropriate shocks can appear early. HCM-specific research should therefore report time-dependent outcomes, generator changes, lead revisions, infection treatment, and crossover to another pacing or defibrillation strategy.
Researchers and clinicians can review current and archived electrophysiology evidence through the journal’s arrhythmia research collection, including studies that place device outcomes within broader HCM management pathways.
Complications And Quality Of Life
The main advantage of an S-ICD is the absence of a transvenous lead. This can reduce risks associated with venous access, lead fracture, lead dislodgement, and systemic infection. It may also simplify future lead management in young patients. Nevertheless, the S-ICD has its own hardware profile, including the possibility of pocket discomfort, erosion, electrode migration, infection, and the need for surgical revision.
Shock burden is a major patient-centered outcome. Even an appropriate shock can be painful and psychologically distressing, while inappropriate shocks may reduce confidence in the device and affect physical activity. HCM patients may be active and may experience marked changes in heart rate or morphology during exercise, making individualized detection zones and post-implant testing particularly valuable.
A TV-ICD can offer ATP and pacing that may reduce shocks in selected tachycardia patterns. Conversely, an S-ICD may be preferable for a patient who has no bradycardia, resynchronization, or ATP requirement and who places a high value on avoiding intravascular hardware. Shared decision-making should address both the probability of future arrhythmia and the likely consequences of each therapy.
Patient Selection And Technical Planning
The decision begins with a standard HCM sudden-death risk assessment, incorporating clinical history, imaging, family history, ventricular function, nonsustained ventricular tachycardia, unexplained syncope, apical aneurysm, and the extent of late gadolinium enhancement where relevant. An ICD indication should be established independently of the device type. The S-ICD is not a substitute for risk stratification.
An S-ICD is most attractive when the patient has preserved bradycardic function, no need for CRT, no sustained monomorphic ventricular tachycardia likely to respond to ATP, and suitable sensing vectors. Screening should be performed in more than one posture, with attention to exercise-related morphology when the clinical context warrants it. Defibrillation testing and careful lead positioning remain important parts of implantation.
A TV-ICD may be favored when there is existing pacing dependence, significant sinus-node or atrioventricular-node disease, recurrent monomorphic ventricular tachycardia, a need for CRT, or a likely future need for ATP. In patients with borderline indications, anticipated disease progression and access to specialist follow-up should be incorporated into the decision.
Practical Recommendations For Follow-Up
Long-term management is essential because HCM phenotype and arrhythmic risk can evolve. Device clinics should review stored electrograms, sensing integrity, shock episodes, battery status, and changes in rhythm or ventricular function. Remote monitoring can help identify abnormalities earlier, but it does not replace clinical assessment after syncope, palpitations, or a shock.
Programming should aim to minimize unnecessary therapy while preserving protection against rapid ventricular arrhythmias. Rate thresholds, detection duration, discrimination settings, and ATP options should reflect the selected platform and the patient’s arrhythmic history. Exercise, atrial fibrillation, and medication changes can alter the balance between sensitivity and specificity.
- Confirm that no current pacing, ATP, or resynchronization indication has been overlooked.
- Perform comprehensive S-ICD sensing screening in relevant postures and consider exertional assessment.
- Discuss the expected benefits and limitations of shocks, ATP, bradycardia pacing, and future system changes.
- Use remote monitoring and structured review of inappropriate therapy mechanisms.
- Reassess ventricular function, symptoms, arrhythmia burden, and HCM risk markers throughout follow-up.
Integrating Device Evidence Into Care
The strongest case for an S-ICD in HCM is a young patient who needs protection from sudden cardiac death but has no indication for pacing or ATP. Avoiding an intracardiac lead can be particularly valuable when venous preservation, infection prevention, or future device procedures are major concerns. The benefit is less clear when the patient has recurrent monomorphic ventricular tachycardia or progressive conduction disease.
A TV-ICD remains an important option because its broader therapeutic capacity can prevent shocks through ATP and provide support for bradycardia or dyssynchrony. Its disadvantages, including intravascular lead complications and systemic infection risk, must be weighed against those capabilities rather than treated as universal reasons to select an extravascular system.
The available comparative outcomes support an individualized strategy rather than a single preferred device for all patients with HCM. Clinicians should interpret registry findings alongside anatomy, arrhythmia mechanism, anticipated pacing needs, body habitus, activity level, and patient preferences. Explore peer-reviewed device and electrophysiology updates, including leadless pacing experience, to place emerging leadless and extravascular technologies in the context of long-term device planning. Use the evidence to structure a shared decision, document the rationale clearly, and match the system to the patient’s present and foreseeable clinical needs.